ClinicalTrials.gg
CompletedNCT01710696Updated Feb 28, 2017

Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome

A Phase 3 interventional study of 17-beta estradiol and 17-beta estradiol in Genetic Disorder and Turner Syndrome, sponsored by Novo Nordisk A/S. Completed at 28 sites in Spain. Open to female participants. Per ClinicalTrials.gov, last updated 2017-02-28.

Primary conditionTurner SyndromeRegistry: Genetic Diseases, InbornReclassifiedWhy we changed it
Registry
Genetic Diseases, Inborn — the first condition term the registry derived for this study.
ClinicalTrials.gg
Turner Syndrome
Why
  1. The study's listed conditions name Turner Syndrome, a narrower term within Genetic Diseases, Inborn.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 14 years 2 months after the study started (first participant enrolled Jul 1998, registered Oct 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Turner Syndrome by Novo Nordisk A/S — none open to participants now, 2 under way, 2 of them phase 3. Turner Syndrome · Novo Nordisk A/S.

Started
1998
the only one that year
Phase 3
5 of 12
none open now
Registered
9th of 12
by date

Among the 12 studies in Turner Syndrome by Novo Nordisk A/S, this one is the only one that started in 1998, is one of 5 in phase 3, and was the 9th registered.

Turner Syndrome

125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.

Browse Turner Syndrome studies →

Open to participants now

None of the 12 studies in Turner Syndrome by Novo Nordisk A/S is open now. The open studies under Turner Syndrome, anywhere →

Who these studies take

Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Turner Syndrome by Novo Nordisk A/S as a file.
02

Study summary

This trial is conducted in Europe. The aim of the trial is to induce normal pubertal development in girls with Turner Syndrome in accordance with that of their peers and their individual state psychosocial maturation.

03

Conditions studied

  • Genetic Disorder
  • Turner Syndrome

Browse trials for

04

In context

Turner Syndrome Reclassified

125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.

This study's enrollment of 50 is below the median of 67 across 52 interventional studies indexed under Turner Syndrome.

Browse Turner Syndrome studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Turner Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Genetic Diseases, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Turner Syndrome
  • Treatment with growth hormone
  • Bone age minimum 12 years and maximum 14 years
  • Clear signs of ovarian insufficiency
  • Well documented growth rate during the last 12 months

Exclusion criteria

Exclusion Criteria:

  • Signs of spontaneous puberty
  • Known or suspected to trial product
  • Acute or chronic liver disease
  • Previous treatment with estrogen
  • Undiagnosed abnormal genital bleeding
  • Known thyroid diseases not adeadequately treated
  • Porphyria
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Individual dose

    Drug: 17-beta estradiol

  • Experimental
    Fixed dose

    Drug: 17-beta estradiol

Interventions

  • 5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally

  • 0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally

07

What researchers measure

Primary outcomes

  1. Pubertal stage assesed by Tanner score

  2. FSH (Follicle Stimulating Hormone) levels

Secondary outcomes

  1. Height velocity

  2. Pubertal stage assessed by Tanner score: Breast, pubic hair, axillary hair

  3. Adverse events

08

Study locations

28 sites
  • Novo Nordisk Investigational Site
    Alicante, 03010, Spain
  • Novo Nordisk Investigational Site
    Badajoz, 06080, Spain
  • Novo Nordisk Investigational Site
    Baracaldo, 48903, Spain
  • Novo Nordisk Investigational Site
    Cáceres, 10002, Spain
  • Novo Nordisk Investigational Site
    Córdoba, 14004, Spain
  • Novo Nordisk Investigational Site
    El Palmar, 30120, Spain
  • Novo Nordisk Investigational Site
    Elche, 3203, Spain
  • Novo Nordisk Investigational Site
    Esplugues Llobregat, 08950, Spain
  • Novo Nordisk Investigational Site
    Granada, 18012, Spain
  • Novo Nordisk Investigational Site
    Jaén, 23007, Spain
  • Novo Nordisk Investigational Site
    La Laguna, 38320, Spain
  • Novo Nordisk Investigational Site
    Las Palmas, 35016, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28007, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28009, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28034, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28040, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28041, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28046, Spain
  • Novo Nordisk Investigational Site
    Málaga, 29011, Spain
  • Novo Nordisk Investigational Site
    Salamanca, 37007, Spain
  • Novo Nordisk Investigational Site
    Santa Cruz de Tenerife, 38010, Spain
  • Novo Nordisk Investigational Site
    Santander, 39008, Spain
  • Novo Nordisk Investigational Site
    Santiago de Compostela, 15705, Spain
  • Novo Nordisk Investigational Site
    Sevilla, 41013, Spain
  • Novo Nordisk Investigational Site
    Tarrasa, 08227, Spain
  • Novo Nordisk Investigational Site
    Valencia, 46026, Spain
  • Novo Nordisk Investigational Site
    Valladolid, 47011, Spain
  • Novo Nordisk Investigational Site
    Zaragoza, 50009, Spain
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 1998 to primary completion in Jul 2004, 72 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2012
First posted
Oct 19, 2012
StartActual
Jul 23, 1998
Primary completionActual
Jul 26, 2004
CompletionActual
Jul 26, 2004
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01710696
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 19, 2012
Start date
Jul 23, 1998
Primary completion
Jul 26, 2004
Completion
Jul 26, 2004
Last update
Feb 28, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion